MARKET

ZYME

ZYME

Zymeworks
NYSE

Real-time Quotes | Nasdaq Last Sale

6.32
0.00
0.00%
Opening 09:36 06/24 EDT
OPEN
6.28
PREV CLOSE
6.32
HIGH
6.36
LOW
6.26
VOLUME
14.75K
TURNOVER
18.33K
52 WEEK HIGH
39.41
52 WEEK LOW
4.560
MARKET CAP
365.11M
P/E (TTM)
-1.4281
1D
5D
1M
3M
1Y
5Y
Sector Update: Health Care Stocks Remain Lower in Late Friday Trading
MT Newswires · 06/10 15:47
BRIEF-Zymeworks Adopts Limited-Duration Shareholder Rights Plan
reuters.com · 06/10 13:58
Drug developer Zymeworks adopts 'poison pill' to keep All Blue at bay
reuters.com · 06/10 13:55
Zymeworks adopts shareholder rights plan after All Blue Falcons proposal
The board of clinical-stage biopharmaceutical company Zymeworks (NYSE:ZYME) adopted a limited-duration shareholder rights plan, intending to enable shareholders to realize the full value of their investment. The moves comes in
Seekingalpha · 06/10 13:33
Sector Update: Health Care Stocks Lower in Afternoon Trading
MT Newswires · 06/10 13:16
Zymeworks Adopts Limited-Duration Shareholder Rights Plan, Enabling All Shareholders to Realize Full Value of Company
VANCOUVER, British Columbia & SEATTLE, June 10, 2022--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that its board of directors (the "Board") has adopted ...
Business Wire · 06/10 13:15
Zymeworks Adopts Shareholder Rights Plan to Fend Off Acquisition
MT Newswires · 06/10 09:54
Analyst Ratings for Zymeworks
Over the past 3 months, 5 analysts have published their opinion on Zymeworks (NYSE:ZYME) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the u...
Benzinga · 05/27 15:45
More
No Data
Learn about the latest financial forecast of ZYME. Analyze the recent business situations of Zymeworks through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

41.67%Strong Buy
33.33%Buy
25.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ZYME stock price target is 24.45 with a high estimate of 45.00 and a low estimate of 7.00.
High45.00
Average24.45
Low7.00
Current 6.30
EPS
Actual
Estimate
-1.34-1.00-0.67-0.33
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 172
Institutional Holdings: 51.58M
% Owned: 89.29%
Shares Outstanding: 57.77M
TypeInstitutionsShares
Increased
52
17.49M
New
29
4.26M
Decreased
19
10.25M
Sold Out
22
3.87M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.67%
Pharmaceuticals & Medical Research
+2.48%
Key Executives
Chairman/President/Chief Executive Officer/Director
Kenneth Galbraith
Chief Financial Officer/Senior Vice President
Christopher Astle
Chief Operating Officer
Neil Klompas
Other
Neil Josephson
Lead Director/Independent Director
Lota Zoth
Independent Director
Troy Cox
Independent Director
Kenneth Hillan
Independent Director
Susan Mahony
Independent Director
Kelvin Neu
Independent Director
Hollings Renton
Independent Director
Natalie Sacks
No Data
No Data
About ZYME
Zymeworks Inc. is a clinical-stage biopharmaceutical company that is engaged in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer. Its lead product candidate is zanidatamab, a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its product candidate ZW49, combines the design of zanidatamab with its ZymeLink ADC platform, comprised of its cytotoxin and cleavable linker. The Company operates through a number of platforms, including Azymetric, ZymeLink, EFECT and ProTECT. Its Azymetric is a bispecific platform that enables therapeutic antibodies to simultaneously bind multiple distinct locations on a target or to multiple targets. Its ZymeLink, which is an antibody-drug conjugate (ADC) platform comprised of cytotoxins and the linker technology used to couple these cytotoxins to tumor-targeting antibodies or proteins.

Webull offers kinds of Zymeworks Inc stock information, including NYSE:ZYME real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZYME stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZYME stock methods without spending real money on the virtual paper trading platform.